News
Pharmasav update March
2010Pharmasav is pleased to announce that its financial statements for the year ending
November 2009 will be lodged at Companies House in the near future. While Pharmasav made a small loss in the financial year,
all research and development expenditure was written off, and sales volume continued to increase. The Shareholders are satisfied
with progress to date, although they recognise it is somewhat behind the original development plan for the Company.The present regulatory environment becomes ever more complicated, and the Company has made considerable efforts to
satisfy regulations being imposed by the European authorities. The Company has presented extensive dossiers of information
to provide evidence of efficacy and product safety. This has been both time-consuming and resource absorbing for the Company.
The Authorities are reviewing submissions from numerous manufacturers and suppliers, and the timescale for approval is uncertain.Following successfully attending and exhibiting at the 2009 Vitafood Exhibition which is held annually in Geneva,
considerable interest was generated in our nutraceutical products. As a result, Pharmasav has appointed a European marketing
partner to help develop our overseas markets. They have considerable experience in pharmaceutical distribution and already
solicited expressions of interest from potential distributors. Samples have been sent for evaluation, and we hope to enter
into agreements in the next 12 months to allow our products have considerably greater presence outside the United Kingdom.Yvette Hastings Managing Director said "we look forward to the future with confidence. Our natural menopause
product has been well received and gained enthusiastic use by satisfied customers, who have found it most helpful. The range
of applications for our PollenAid product is growing, and small-scale consumer trials of one novel application is underway.
We will be making further announcements in due course " _________________________________________________________________________________________________________________European Medicines Agency Sept 2009Pharmasav
Ltd continues to be recognised as a Micro, Small or Medium-sized Enterprise (SME) and benefits from the provisions for administrative
and financial assistance laid down in Regulation (EC) No 2049/361/EC. This recognition needs to be renewed on or before 30
November 2010.Notes to editors.
Further details can be obtained from Yvette
Hastings, Yvette@Pharmasav.com_________________________________________________________________________________________________________________Vitafoods in Geneva 2009. May 2009Pharmasav
has a strategy of developing its international operations and once again was present at the Vitafoods International and Finished
Products trade show in Geneva in the first week in May. Yvette Hastings and Olivier Demongeot
represented the Company, and considerable interest was generated during the show. The opportunity
was taken to showcase the two Pharmasav products available for the market – TAM and PollenAid.TAM our menopausal product, which was specifically developed for women at the peri- and post-menopause stages in
their lives, appealed to international buyers. Many organisations are looking for natural plant products to promote well-being.
TAM has proved efficacious and popular with many clients. A UK consumer study demonstrated that 94% of women saw significantly
improved wellbeing with 93% enjoying increased energy/reduced fatigue. In this study 86% of women found an improvement in
emotional wellbeing and 83% noted a very welcome improvement in sleep. We were also delighted
to meet with Cynthia and Heather May of Graminex who were visiting the exhibition. Graminex supplies PollenAid to Pharmasav
for distribution. PollenAid is concentrated flower pollen, which provides essential nutrients
including Essential and Non-Essential Amino Acids, B-Complex Vitamins, Choline, Inositol, Vitamin C, Enzymes, and Flavonoids.
It promotes bladder health and generally improves the symptoms of nocturia (excessive urination at night) and incomplete emptying
of the bladder. It is a very well tolerated dietary supplement.Pharmasav is looking to undertake
a UK consumer trial in connection with PollenAid later in 2009, and further reports will be made in due course.Yvette Hastings stated "We have a number of opportunities to expand the international and domestic market for
our products. I am greatly encouraged by the interest expressed by some major players."Notes to
editors.
Further details can be obtained from Yvette Hastings, Yvette@Pharmasav.com_________________________________________________________________________________________________________________Possible Side-Effect of PollenAid Product IdentifiedMarch 2009While the effectiveness of PollenAid in connection with improvement of the male prostate and urinary function is
well-documented and medically recognised, Pharmasav has recently become aware of a potential side-effect, which may or may
not be considered a problem.In the United States and elsewhere world, products containing very
similar pollen are advertised and actively marketed to thousands of satisfied users to improve their sex lives. It is said
on one website to "increase men’s sexual vitality. Over the past several decades, it has been used by millions
of men in Europe, Japan and throughout Asia for the improvement of sexual performance and recovery". The marketing company
goes on to say "users typically experience stronger ejaculation with increase in semen volume, seminal fluid and more
sperm release."Don Hammond, Company Secretary, said "I have used this product over
the last two years, and I am well satisfied with its value. I do not consider such a side-effect to be a significant problem".Notes to editors
PollenAid contains some 39 vitamins, minerals, and caretenoids, 23 essential
amino acids, 98 enzymes, polar and neutral lipids, 20 fatty acids, prostaglandins, phytosterols, and long chain hydrocarbons.
Pharmasav Appoints NutraFX as a UK DistributorNovember 2007Pharmasav is pleased to announce that it has reached agreement with NutraFX
to distribute both PollenAid and the menopause product, which was formulated by Pharmasav and its associates.The menopause product is a reformulation using ingredients which have traditionally been used in Chinese medicine.
The natural plant products containing phytoestrogens have been shown to interact with oestrogen receptors in a woman’s
body. As a result many women find that they provide symptomatic relief of many of the problems associated with menopause.
The product is manufactured in Asia under pharmaceutical manufacturing conditions, and subject to stringent quality control
procedures.The PollenAid product is manufactured and sold widely in the world, and has been
shown to be of benefit to many people suffering from kidney or prostate problems. It is an extract of rye grass pollen, and
PollenAid does not use solvents in the course of its production. Similar products in the market largely rely on solvents in
the extraction process; this was not acceptable to Pharmasav.Lee Hastings, Chief Executive
of NutraFX, stated "I am delighted to be able to make these products available to our customers. The menopause product
has brought relief to many women, and this formulation is particularly effective. The PollenAid prostate tablets have been
shown in well publicised trials to provide relief for the majority of men who experience benign prostate enlargement as they
grow older."Don Hammond, Company Secretary, stated "we are delighted to have appointed
NutraFX as a distributor, and look forward to a long and mutually beneficial relationship. They have a successful web-based
marketing system, which will provide wide availability of these desirable products."
 |
|
PollenAid Distribution Deal SecuredJuly 2007On 20 July 2007, Pharmasav was appointed distributor of PollenAid and pollen extract bulk products by Graminex, the
respected manufacturer based in Saginaw, USA.The Graminex product was identified by Pharmasav
as being particularly attractive as it is extracted without using solvents, alternative products mostly use aggressive solvent
extraction processes.PollenAid has been shown in many studies to relieve the symptoms of a
benignly enlarged prostate, which is common in many older men. It is also suggested that it has many other benefits, but not
all of the benefits have been subject to rigourous clinical trials. For example, a search of the literature indicates that
the ingredients in PollenAid may have potential to treat prostatitis, prostate cancer, symptoms of menopause and PMS, and
to reduce cholesterol. Without further evidence, Pharmasav is not presently making such claimsPollenAid
incorporates extracts of concentrated rye grass pollen. A search of the BMJ website, http://www.besttreatments.co.uk/btuk/conditions/8850.html
identified the following statement: "Rye grass pollen extracts may help your symptoms, especially if you need to keep
getting up in the night to urinate. In studies, 7 out of 10 men taking rye grass pollen said their symptoms improved. This
compared with 3 out of 10 men taking a dummy treatment. Also, 6 out of 10 men said they had to get up at night less often
after taking rye grass pollen, compared with 3 out of 10 men who took a placebo."The company
looks forward to announcing its first product distribution agreement to make the product available in the United Kingdom in
the near future.Don Hammond, Company Secretary, said "this is a product with a huge potential
market. Most older men suffer from an enlarged prostate, and PollenAid has been shown in many case studies to be effective
for many men in reducing symptoms. Provided I take the tablets, my wife is likely to benefit from a better night’s sleep!"Note to editorsClinical evidence demonstrates the health benefits of PollenAid for
sufferers with either kidney or prostate problems. A simple web search will identify these studies and further details can
be found on the www.Graminex.com web site.Pharmasav focuses on products which have established
safety and efficacy records. The company’s core values are to be trustworthy, innovative, flexible, professional and
commercially ethical.
Pharmasav
Submits Food Standard Agency Health Claims for Menopause Product and PollenAidOctober
2007Pharmasav is pleased to announce that it has submitted within the necessary timescale the
health claims required under current legislative changes.Yvette Hastings, Chief Executive,
stated "there are increasing pressures on smaller companies, and the regulatory process is particularly onerous. It is
not entirely clear how the approval process will operate, and there appears to be no detailed system to appeal unreasonable
decisions. Pharmasav is committed to the highest standards of production and we intend to supply only world-class products
to the market."Notes to editors
The products in question are as follows:
PollenAid, which comprises Rye Pollen (Secale Cereale L) at a suggested use per day of 720mg of water-soluble extract and
36mg of fat-soluble extract from organic sources. There is considerable evidence that this product promotes bladder health
for both male and female sufferers, although many of the studies have concentrated on male sufferers with prostate problems.
Menopause product utilises natural vegetable sourced Phytoestrogens extracted from Vigna radiata at a suggested use of between
150mg & 600mg per day as required. Vigna radiate is a traditional Asian food from which natural Phytoestrogens can be
produced. Phytoestrogens are widely used as a natural alternative to pharmaceutical products prescribed by doctors for the
relief of menopausal symptoms.
European
Medicines Agency RecognitionOctober 2006Pharmasav Ltd is
pleased to announce that it has been assigned SME status by the European Medicines Agency. This recognition entitles Pharmasav
to various European benefits, and confirms and acknowledges the status of the company within the healthcare market in the
United Kingdom.Yvette Hastings, Chief Executive Officer, said "this is a further important
and significant step in the foundation of the company. We have several products in development or negotiation."
Toshiyuki Kitaura - Japanese Consultant AppointedNovember 2005Pharmasav Ltd is pleased to announce that it has reached agreement with
Toshiyuki Kitaura in Tokyo to act as a consultant.Toshiyuki Kitaura will be advising Pharmasav
on the Japanese health market and products to identify products that might be distributed within Britain and the EEC. Such
products might include pain control patches, antiseptic sprays together with tonics, vitamins and herbal products.Yvette Hastings, Chief Executive Officer, said "this is a further step in our strategy to identify efficacious
new products to benefit consumers. Toshiyuki Kitaura is enormously respected for his expertise and we are delighted that he
has agreed to work with us."
New
Healthcare Company in the North-WestNovember 2005Pharmasav
Ltd is pleased to announce that it was incorporated and registered on 17 November 2005. The company number is 5626032.Pharmasav has been established to develop and market consumer health care products ranging from functional foods,
nutraceutical products, together with items for the beauty and speciality sectors. The company intends to establish a base
in Singapore to handle the Asian market.The company will be focusing on products which have
established safety and efficacy records. Development of new products will be done in conjunction with global speciality product
manufacturers overseen by leading formulation experts, assisted by our academic associates.The
company’s core values are to be trustworthy, innovative, flexible, professional and commercially ethical.The company looks forward to announcing its first product to be available in the United Kingdom in the near future.Yvette Hastings, Chief Executive Officer, said "this is a major opportunity to develop products which the consumer
will want to use. We have a number of exciting ideas to bring to the market."
|
